Study	Reason for exclusion
Aberg-Wisted 2000	RCT of sertraline versus paroxetine for outpatients with major depression. Investigators examined effects of comorbid Axis II disorder by personality disorder cluster. No indication that any subgroup of participants had AsPD. Excluded because of lack of a placebo control group
Agosti 2002	RCT of fluoxetine versus imipramine versus placebo in outpatient with major depression. Excluded because no participants were reported with a diagnosis of AsPD
Allen 1976	Crossover trial in which 41 “sociopathic” prisoners received a random sequence of four active substances (amphetamine, caffeine, imipramine and chlorpromazine) and one inactive placebo. Excluded because participants were not assessed for possible diagnosis of AsPD
Alpert 1990	RCT of nadolol versus placebo for violent psychiatric patients. Excluded because nadolol is not a drug with known psychotropic properties, because none of the participants had a diagnosis of AsPD, and because most had a major functional mental illness (i.e. schizophrenic disorder, schizoaffective disorder or bipolar disorder)
Battaglia 1999	RCT of depot fluphenazine (‘low dose’ versus ‘ultra low dose’) for multiple suicide attempters in the emergency department. Cluster B personality disorder was represented in the sample, but unclear whether any participants had an AsPD diagnosis. Excluded because of lack of a placebo control group
Black 1994	RCT comparing fluvoxamine, cognitive therapy and placebo for participants with panic disorder. Excluded because no specific personality disorder diagnoses were reported and there was no indication that any subgroup had AsPD
Coccaro 1997	RCT comparing fluoxetine with placebo in adult outpatients with personality disorder and a history of impulsive aggression and irritability. Excluded because only four participants with AsPD were diagnosed, which is too few to allow calculation of means and SDs when randomised to two treatment conditions
Ekselius 1998	RCT of sertraline versus citalopram in depressed patients in primary care. Excluded because no assessment of AsPD was made, and because there was no placebo control condition
Fournier 2008	RCT comparing paroxetine, placebo and cognitive therapy in outpatients with depressive disorder. Excluded because presence of AsPD was an exclusion criterion for the trial
Joyce 2003	RCT comparing fluoxetine with nortriptyline in patients with major depression. Differential drug response was compared in three groups; with BPD, with other personality disorder and with no personality disorder. Six participants had AsPD. Excluded because of lack of a placebo control group
Kool 2007	RCT comparing psychodynamic supportive therapy plus pharmacotherapy with pharmacotherapy alone for depressive disorder in adult patients (article in Dutch). Excluded because there was no placebo control condition and only three participants had an AsPD diagnosis
Mattes 1990	RCT comparing carbamazepine versus propranolol for temper outbursts. A subgroup of participants (n = 8) had AsPD. Excluded because of lack of a placebo control condition
Mattes 2005	RCT comparing oxcarbazepine with placebo in outpatients with impulsive aggression. Excluded because no diagnosis of personality disorder was made
Mattes 2008	RCT comparing levetiracetam with placebo in outpatients with impulsive aggression. Excluded because no diagnosis of personality disorder was made
Nickel 2005	RCT comparing topiramate with placebo in male outpatients with aggression. Excluded because no diagnosis of personality disorder was made
Noyes 1991	RCT comparing alprazolam, diazepam and placebo in patients with panic disorder. Investigators examined the effect of co-morbid personality disorder traits on treatment outcome, but report only mean PDQ (trait) scores. Excluded because no indication that any participants with a diagnosis of AsPD were randomised
Patience 1995	RCT in which 113 participants meeting DSM-III criteria for major depression were randomly assigned to one of four conditions of which one was amitriptyline and one was routine primary care. Excluded because only eight participants were diagnosed with AsPD which is too few to allow calculation of means and SDs when randomised to four treatment conditions
Shea 1990	RCT in which 250 participants with a primary diagnosis of major depressive disorder were randomised to four conditions, of which one was imipramine plus clinical management and one was placebo plus clinical management. AsPD was an exclusion criterion